These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15481918)

  • 21. Mycobacterial 65,000 MW heat-shock protein shares a carboxy-terminal epitope with human epidermal cytokeratin 1/2.
    Rambukkana A; Das PK; Krieg S; Young S; Le Poole IC; Bos JD
    Immunology; 1992 Oct; 77(2):267-76. PubMed ID: 1385316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outer-membrane antigen expression by Moraxella (Branhamella) catarrhalis influences pulmonary clearance.
    Kyd JM; Cripps AW; Murphy TF
    J Med Microbiol; 1998 Feb; 47(2):159-68. PubMed ID: 9879959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma.
    Thurner L; Hartmann S; Fadle N; Regitz E; Kemele M; Kim YJ; Bohle RM; Nimmesgern A; von Müller L; Kempf VAJ; Weniger MA; Neumann F; Schneider N; Vornanen M; Sundström C; de Leval L; Engert A; Eichenauer DA; Küppers R; Preuss KD; Hansmann ML; Pfreundschuh M
    Nat Commun; 2020 May; 11(1):2465. PubMed ID: 32424289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inducers of autoimmune reactions in patients with trigeminal neuralgia].
    Mordvinov GV
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (1):73-7. PubMed ID: 7520653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution.
    Augustyniak D; Seredyński R; McClean S; Roszkowiak J; Roszniowski B; Smith DL; Drulis-Kawa Z; Mackiewicz P
    Sci Rep; 2018 Mar; 8(1):4955. PubMed ID: 29563531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines for Moraxella catarrhalis.
    McMichael JC
    Vaccine; 2000 Dec; 19 Suppl 1():S101-7. PubMed ID: 11163472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoinformatics Identifies a Lactoferrin Binding Protein A Peptide as a Promising Vaccine With a Global Protective Prospective Against Moraxella catarrhalis.
    Yassin GM; Amin MA; Attia AS
    J Infect Dis; 2016 Jun; 213(12):1938-45. PubMed ID: 26908723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of hospital isolates of Moraxella (Branhamella) catarrhalis by SDS-PAGE of whole-cell proteins, immunoblotting and restriction-endonuclease analysis.
    McKenzie H; Morgan MG; Jordens JZ; Enright MC; Bain M
    J Med Microbiol; 1992 Jul; 37(1):70-6. PubMed ID: 1625319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens.
    Braun JM; Beuth J; Blackwell CC; Giersen S; Higgins PG; Tzanakaki G; Unverhau H; Weir DM
    Vaccine; 2004 Feb; 22(7):898-908. PubMed ID: 15040943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Respiratory Pathogen Moraxella catarrhalis Targets Collagen for Maximal Adherence to Host Tissues.
    Singh B; Alvarado-Kristensson M; Johansson M; Hallgren O; Westergren-Thorsson G; Mörgelin M; Riesbeck K
    mBio; 2016 Mar; 7(2):e00066. PubMed ID: 27006460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model.
    Liu DF; McMichael JC; Baker SM
    Infect Immun; 2007 Jun; 75(6):2818-25. PubMed ID: 17403868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal, opsonophagocytic and anti-adhesive effectiveness of cross-reactive antibodies against Moraxella catarrhalis.
    Augustyniak D; Piekut M; Majkowska-Skrobek G; Skała J
    Pathog Dis; 2015 Apr; 73(3):. PubMed ID: 25743473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2.
    Tan TT; Christensen JJ; Dziegiel MH; Forsgren A; Riesbeck K
    Infect Immun; 2006 Nov; 74(11):6377-86. PubMed ID: 16966403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of immunization of pulmonary clearance of Moraxella catarrhalis in an animal model.
    Maciver I; Unhanand M; McCracken GH; Hansen EJ
    J Infect Dis; 1993 Aug; 168(2):469-72. PubMed ID: 8335988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Pneumococcal Conjugate Vaccine on the Natural Antibodies and Antibody Responses Against Protein Antigens From Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Children With Community-acquired Pneumonia.
    Andrade DC; Borges IC; Adrian PV; Meinke A; Barral A; Ruuskanen O; Käyhty H; Nascimento-Carvalho CM
    Pediatr Infect Dis J; 2016 Jun; 35(6):683-9. PubMed ID: 26954601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Collagen VI Is Upregulated in COPD and Serves Both as an Adhesive Target and a Bactericidal Barrier for Moraxella catarrhalis.
    Abdillahi SM; Bober M; Nordin S; Hallgren O; Baumgarten M; Erjefält J; Westergren-Thorsson G; Bjermer L; Riesbeck K; Egesten A; Mörgelin M
    J Innate Immun; 2015; 7(5):506-17. PubMed ID: 25925694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood.
    Goldblatt D; Turner MW; Levinsky RJ
    J Infect Dis; 1990 Nov; 162(5):1128-35. PubMed ID: 1700025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response in rabbits to serotype-specific determinants in lipopolysaccharides from Moraxella catarrhalis.
    Rahman M; Holme T
    J Med Microbiol; 1996 May; 44(5):348-54. PubMed ID: 8636949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total genome polymorphism and low frequency of intra-genomic variation in the uspA1 and uspA2 genes of Moraxella catarrhalis in otitis prone and non-prone children up to 2 years of age. Consequences for vaccine design?
    Hays JP; van der Schee C; Loogman A; Eadie K; Verduin C; Faden H; Verbrugh H; van Belkum A
    Vaccine; 2003 Mar; 21(11-12):1118-24. PubMed ID: 12559789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immuno-blot analysis of antigens of Mycobacterium w: a candidate anti-leprosy vaccine using monoclonal antibodies and patient sera.
    Ganju L; Mukherjee R; Batra HV; Talwar GP
    Zentralbl Bakteriol; 1990 Aug; 273(3):378-85. PubMed ID: 1698376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.